Cure4Lupus.org News:         
  Twitter Facebook Email
 

Cure4Lupus.org
For Lupus Fighters, By Lupus Fighters.
Promoting Lupus Awareness and Research to Find a Cure.
Providing Information, Support, & Lupus Awareness Products.


Lupus Research News

We try to keep up with all the latest news that is related to Lupus.

New Lupus Research NewsUCB Announces New Results From Phase 2b Open-Label Extension Study Evaluating The Long-Term Effects Of Epratuzumab In SLE UCB have announced new data from an open-label extension (SL0008) of the EMBLEM™ phase 2b study evaluating the long-term effects of epratuzumab treatment in adult patients with moderate-to-severe systemic lupus erythematosus (SLE).

Link Between Uranium Exposure And Increased Lupus Rate People living near a former uranium ore processing facility in Ohio are experiencing a higher than average rate of lupus, according a new study conducted by scientists at the University of Cincinnati and Cincinnati Children's Hospital Medical Center.

New hope for lupus patients A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France. The peptide, known as P140/LupuzorTM, is well tolerated by patients and leads to regression of the disease. Under the CNRS patent, ImmuPharma-France, which funded the trial, has an exclusive license to use the peptide. Now the final phase of clinical tests should soon confirm these results and contribute to the development of a drug without the side effects of existing treatments, which use cortico-steroids and immunosuppressants. These results are published online in the Annals of the Rheumatic Diseases.

S.L.E. Lupus Foundation “Turns Lupus Research Upside Down” at Gala 2012 More than 700 members of New York City’s philanthropic, government, business and health care communities joined forces tonight as the S.L.E. Lupus Foundation hosted its Gala 2012 to Turn Lupus Research Upside Down. Held at The American Museum of Natural History, the world’s largest gathering for lupus was hosted by Willie Geist, new co-host of NBC’s Today Show and MSNBC’s Morning Joe. The night raised $2.5 million to turn the tables on lupus with novel innovative research that is producing the pivotal discoveries to improve treatments and uncovering the root causes of lupus that can lead to a cure.

The Impact Of Rheumatoid Arthritis And Lupus On Joint Replacement Surgery Outcomes Two new studies by researchers at Hospital for Special Surgery have overturned common beliefs about joint replacement in patients with lupus and rheumatoid arthritis (RA).In one study, researchers demonstrated that RA patients who undergo a knee replacement can expect outcomes that are similar to individuals undergoing the operation for osteoarthritis.

Alliance For Lupus Research And Pfizer’s Centers For Therapeutic Innovation Announce Novel Research Collaboration With Leading Academic Medical CentersAlliance for Lupus Research (ALR) and Pfizer’s Centers for Therapeutic Innovation (CTI) are partnering to discover new therapies for patients living with lupus.  As part of this first-of-its-kind collaboration in lupus, ALR and CTI will co-fund novel translational research projects driven by leading academic medical centers within the CTI network.

New anti-interferon alpha therapy for lupus nabs $5.8MThe approval of Human Genome Sciences/GlaxoSmithKline’s Benlysta last year ended a drought of new drug approvals for the autoimmune disease lupus that had lasted more than half a century.  A lengthy pipeline of drugs is hoping to follow suit, including a preclinical biologic compound from a University of Washington spinoff that is hoping to progress to clinical trials next year.  Resolve Therapeutics has just completed a $5.8 million series B, following up a $2 million series A done in 2011. The cash came from previous investors New Science Ventures and Easton Capital, and new investor WRF Capital, the venture investment arm of the Washington Research Foundation.

Lupus Increases Risk For Preeclampsia In PregnancyNew research reports that women with systemic lupus erythematosus (SLE) have a two-fold increase in risk of preeclampsia - a dangerous condition in which pregnant women develop high blood pressure (hypertension) and protein in their urine (proteinuria) after 20 weeks of gestation.

LRI Awards First $1 Million Private Sector Research Grants to Uncover the Root Causes of Lupus That Can Drive to a CureThe Lupus Research Institute (LRI) announced the first $1 million research grants given to lupus investigators by a private research organization. The LRI Distinguished Innovator Initiative was created to address the current lack of treatments in development that could arrest or reverse the disease. The first privately funded awards of this scale in lupus, it challenges the international scientific community to pursue highly promising new ideas on the fundamental causes of lupus that can lead to a cure.

Lupus Patients May Benefit From Vitamin D SupplementsA new clinical study published in BioMedCentral's open access journal Arthritis Research and Therapy provides preliminary evidence that vitamin D supplementation could be considered an immunomodulatory agent for systemic lupus erythematosus (SLE), a debilitating autoimmune disease characterized not only by skin, joint, neurological and renal symptoms, but also by inflammation of tissue linings in the body.

Experimental Test Builds on LRI-Funded Work to Improve Lupus DiagnosisAs with any illness, once it is diagnosed, lupus can be treated. And as with most diseases, the earlier in the process the better. Research originally funded by the LRI has led to a study using computer chip technology to speed up diagnosis.

Researching B Cells Reveals Clues About LupusTo fully grasp an understanding of lupus, leading scientists across the globe are looking to the immune system for answers — particularly the role that B cells play. Autoimmune disease expert, Dr. Peter K. Gregersen, is one such scientist.

Molecule Found That Puts The Brakes On InflammationWe couldn't live without our immune systems, always tuned to detect and eradicate invading pathogens and particles. But sometimes the immune response goes overboard, triggering autoimmune diseases like lupus, asthma or inflammatory bowel disease.

Lupus Gains Attention in America's Fifth Largest NewspaperMore than half a million New Yorkers woke up to news about LRI Coalition member, the S.L.E. Lupus Foundation, in today's edition of the New York Daily News. Our own Tayumika Zurita, Outreach Coordinator Brooklyn Center was featured in an extensive article on her work with the Brooklyn co-op on behalf of the S.L.E. Lupus Foundation.

Upcoming book asks How do you solve a problem like lupusNew book coming out this fall, The Lupus Encyclopedia (Johns Hopkins University Press), is expected to be a definitive work for patients and caregivers. The book is by Dr. Donald Thomas, Jr., Assistant Professor of Clinical Medicine at the Uniformed Services University of the Health Sciences in Bethesda, MD.

New Bill to Advance Research in Autoimmune Diseases Like LupusA new HR Bill 6218 has been introduced to Congress by U.S. Rep. Ann Marie Buerkle (R-NY) that would be good news for lupus as one of the many autoimmune diseases. The bill would create an interdepartmental autoimmune disease coordinating committee including the Assistant Secretary of Health, the Commissioner of Food and Drugs and the Director of the National Institutes of Health among others.

No Added Benefit Proven For Belimumab For Lupus ErythematosusBelimumab (trade name Benlysta ®) has been approved since July 2011 as an add-on therapy for adult patients with the autoimmune disease systemic lupus erythematosus (SLE). This monoclonal antibody is only considered as treatment when the disease is still active in spite of standard therapy

Lupus Patients Benefit From The Power Of New Silicon ChipResearchers at the Stanford University School of Medicine and Intel Corp. have collaborated to synthesize and study a grid-like array of short pieces of a disease-associated protein on silicon chips normally used in computer microprocessors

Increased Risk Of Lupus Possible Following Chronic Exposure To Staph BacteriaChronic exposure to even small amounts of staph bacteria could be a risk factor for the chronic inflammatory disease lupus, Mayo Clinic research shows. Staph, short for Staphylococcus aureus, is a germ commonly found on the skin or in the nose, sometimes causing infections

New Bill to Advance Research in Autoimmune Diseases Like LupusA new HR Bill 6218 has been introduced to Congress by U.S. Rep. Ann Marie Buerkle (R-NY) that would be good news for lupus as one of the many autoimmune diseases. The bill would create an interdepartmental autoimmune disease coordinating committee including the Assistant Secretary of Health, the Commissioner of Food and Drugs and the Director of the National Institutes of Health among others. Its purpose would be to assess national progress on autoimmune disease research, update the national strategic plan, and make recommendations that could possibly be used to develop a national curriculum on autoimmune disease.

Newly Published Finding Provides Clues to Preventing Lupus FlaresFindings from an animal study just published in The Journal of Immunology showed that repeated exposure to staph bacteria could be a cause of lupus or a trigger for a flare-up. Co-author and Mayo Clinic rheumatologist Vaidehi Chowdhary, MD, said they hope to confirm their findings in lupus patients and find a way to prevent flares. Dr. Chowdhary’s team is also exploring whether treating people at risk for lupus to eradicate staph bacteria might prevent lupus from developing.

Shedding Light On Pregnancy Complications And Overturning Common BeliefA study led by Hospital for Special Surgery researchers has demonstrated that women who have a specific type of antibody that interferes with blood vessel function are at risk for adverse pregnancy outcomes and that other antibodies in the same family thought to cause pregnancy complications do not put women at risk


Lupus Research Institute Initiative Results in $1 Million Appropriation for Lupus Medical Education in Fiscal 2013 Senate Committee Bill Funding to Educate Healthcare Professionals in Recognizing and Diagnosing Lupus

Key Step Discovered In Immune System-Fueled InflammationLike detectives seeking footprints and other clues on a television "whodunit," science can also benefit from analyzing the tracks of important players in the body's molecular landscape.

LRI Funded Novel Research on Lupus and the Brain Helping to Explain Pregnancy Loss among Women with LupusWhy is pregnancy loss more common for women with lupus? The answer may come from a seemingly unrelated finding started 10 years ago by noted researcher Betty Diamond, MD at The Feinstein Institute for Medical Research. Dr. Diamond is applying her initial LRI-funded discovery of an autoantibody that attacks the brain to provide a new biological explanation of pregnancy loss in lupus.

Lupus Updates from Major European Rheumatology Meeting (EULAR) 2012Physicians, researchers and patients came together in Berlin last week for the 2012 Annual European Congress of Rheumatology (EULAR). The four-day program covered the gamut of rheumatological diseases and included new advances in basic science, new treatments, and clinical practice. In attendance to represent the Lupus Research Institute (LRI) and report on the key lupus news from the lab and clinic was Dr. Jen Bell, LRI Research Director.

Study Shows Improvement with Benlysta Plus Standard Lupus TreatmentA new study found that belimumab combined with conventional treatment improved biomarkers and clinical disease activity in patients with systemic lupus erythematosus. Study investigators wrote, "Taken together, these results suggest that belimumab treatment does not compromise the immune response to infection."

Study Confirms Need for New Treatments for Kids with LupusBritish study published in the July issue of Arthritis & Rheumatism provides important insights into juvenile lupus, confirming the critical need for new treatments. Despite risk of long-term effects, almost all kids with lupus use corticosteroids; yet the disease still impacts their organs.

Autoimmune Disease Rates Increasing According to a new study the prevalence and incidence of autoimmune diseases, such as lupus, celiac disease, and type 1 diabetes, is on the rise and researchers at the Center for Disease Control and Prevention are unsure why.

Researchers Make Important Breakthrough In Immunology A team of researchers at the IRCM led by Dr. Andre Veillette made an important breakthrough in the field of immunology, which was published online by the scientific journal Immunity. The scientists explained a poorly understood molecular mechanism associated with a human immune disorder known as XLP disease or Duncan's syndrome.

Some Good News About Belly Fat A fatty membrane in the belly called the omentum has until recently been considered somewhat like the appendix - it didn't seem to serve much purpose.But Loyola University Chicago Stritch School of Medicine researchers have found that the omentum appears to play an important role in regulating the immune system.

Test to Predict a Lupus Flare to be Developed Via New Corporate Collaboration XDx, Inc. entered into a collaboration and license agreement with Laboratory Corporation of America(R) Holdings (LabCorp) to collaborate in discovering biomarkers (potential indicators to monitor disease progress and treatment success). LabCorp will develop and commercialize a diagnostic test to predict flares of systemic lupus erythematosus (SLE).

Experimental Lupus Treatment One-Step Closer to Possible Approval The U.S. Food and Drug Administration (FDA) granted fast-track designation for its experimental lupus treatment, Lupuzor. This status means that the review will be given priority to go faster than usual. FDA often grants this accelerated process to drugs that show promise in treating serious, life-threatening medical conditions for which no other drug either exists or works as well.

Lupus Nephritis - New Guidelines Issued Lupus nephritis is a kidney disorder caused by a complication of systemic lupus erythematosus (SLE). Unlike previous guidelines, the new ACR guidelines are specific to lupus nephritis and include newer treatments, techniques for detecting renal disease, as well as treatment of pregnant SLE patients with kidney involvement.

Enlisting �Big Eater� Cells May Prevent Autoimmune Response A Lupus Research Institute (LRI) scientist and his team have discovered a new pathway that helps prevent the immune system from mistaking dying cells as a potential threat. Harnessing this protective process could allow researchers to develop new treatments to prevent destructive immune responses in lupus and other autoimmune diseases such as rheumatoid arthritis.

Women with lupus have chance for safer pregnancies, Oklahoma City expert says For decades, women with lupus were discouraged from having children. Now, a doctor at the Oklahoma Medical Research Foundation says, if they're willing to plan, most women with lupus can safely have a baby.

Epstein Barr Virus Protects Against Autoimmunity�To the surprise of investigating researchers, an animal model of Epstein Barr virus protected lupus-prone mice against development of the autoimmune disease. Earlier work had suggested that EBV might promote the development of autoimmunity

Early Treatment With Rituximab in Newly Diagnosed Systemic Lupus Erythematosus Patients� Objectives. To assess the effectiveness of B-cell depletion therapy (BCDT) as a steroid-sparing treatment in newly diagnosed SLE patients.

EMD Serono Collaborates with Lupus Research Institute to Sponsor Research with Promise for Developing New Treatments� The Lupus Research Institute (LRI) is very pleased to announce a new joint initiative to support innovative research in lupus with EMD Serono, the biopharmaceutical division of global pharmaceutical giant Merck KGaA Darmstadt, Germany

Systemic Lupus and Malignancies Purpose of review Individuals with systemic lupus erythematosus (SLE) have an increased susceptibility to certain types of cancer. Given concerns focused on this issue, we present a review of this important topic.

OMRF researchers identify three lupus genes Three newly confirmed lupus genes are opening new avenues of research at the Oklahoma Medical Research Foundation.��A paper published in the April 6 issue of the American Journal of Human Genetics describes three lupus genes discovered by OMRF researchers as part of a massive international collaboration.

R-Loops Break Walls Of Gene Silencing� Researchers at the University of California, Davis, have figured out how the human body keeps essential genes switched "on" and silences the vast stretches of genetic repeats and "junk" DNA.Frédéric Chédin, associate professor in the Department of Molecular and Cellular Biology, describes the research in a paper published in the journal Molecular Cell.

New Targets For Lupus Treatment Inspired By Natural Method For Clearing Cellular Debris� Cells that die naturally generate a lot of internal debris that can trigger the immune system to attack the body, leading to diseases such as lupus.Now Georgia Health Sciences University researchers report that an enzyme known to help keep a woman's immune system from attacking a fetus also helps block development of these autoimmune diseases that target healthy tissues, such as DNA or joints.

Women With Rheumatoid Arthritis And Lupus Give Birth To Fewer Children� New research shows that more than half of women with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) have fewer children than desired. While patient choice has some influence on the smaller family size, findings published in Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), suggest that higher rates of infertility and miscarriage may also impact the number of offspring born to women with these chronic conditions.

Mutation Drives Viral Sensors To Initiate Autoimmune Disease� A new study uses a mouse model of a human autoimmune disease to reveal how abnormal regulation of the intracellular sensors that detect invading viruses can lead to autoimmune pathology. The research, published online in the journal Immunity by Cell Press, provides key insight into mechanisms that underlie the development of autoimmune disease and may lead to more effective strategies for therapeutic intervention.

DNA Sequence Discovered That Causes The Most Severe Cases Of Lupus A "genetic accelerator" is responsible for the most severe cases of Lupus (systemic lupus erythemathosus), an autoimmune disease: the accelerator, called enhancer HS1.2, speeds up the activity of some critical genes of the immune system involved in the disease.

Reduced Growth and Delayed Puberty in Children with Lupus Children with lupus often face unique challenges because their disease can be more severe and may require more aggressive treatments. Lupus or its treatments may have lasting biological effects. However, little is known about growth and development in children with lupus. The researchers examined possible impairments in growth, such as height, among children with lupus of varying ages and also depending on how long they have had lupus. Possible effects of steroid treatments on height were also specifically examined.

Interview-Driven, Patient-Reported Lupus Damage It is advantageous and useful for people with lupus to be well-informed about their disease activity and its possible effects on their lives. This knowledge can help patients play an active role in their disease as well as keep their physicians attuned to their disease status. Recently, greater emphasis has been placed on patient-reported lupus disease activity. The researchers developed a questionnaire about lupus disease activity which is to be answered by the patients themselves during the course of an interview.

Blood Test May Indicate Lupus Nephritis Activity Inflammation of the kidneys, or lupus nephritis, is a relatively common and potentially severe manifestation of lupus. It can be difficult to accurately identify, however, without a kidney biopsy. The development of new kinds of tests that could help identify lupus nephritis disease and activity without the need for such an invasive procedure could be very useful. The researchers developed a new kind of blood test to help identify lupus nephritis disease and activity among a variety of patients with kidney disease (some with lupus and some without).

Study: Mycophenolate Is Superior To Azathioprine As Treatment For Lupus Nephritis A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis.

Hemodialysis Therapy Preferred By Most Lupus Nephritis Patients With End-Stage Renal Disease Newly published research shows that more patients with end-stage renal disease (ESRD) caused by lupus nephritis choose hemodialysis as their initial kidney replacement therapy over peritoneal dialysis and preemptive kidney transplantation.

American College Of Rheumatology 2011 Annual Meeting: Presentations By NYU Langone Experts Experts from NYU Langone Medical Center will present new research findings and clinical insight into the treatment of rheumatic and bone diseases in a variety of presentations at the American College of Rheumatology (ACR) 2011 Annual Scientific Meeting in Chicago, November 5-9, 2011.

Transportation And Childcare Difficulties Top Reasons For Missed Lupus Appointments The first step towards successful medical care is to see a physician, but for some patients this isn't as simple or easy as it may sound.A study presented at the 2011 Annual Scientific Meeting of the American College of Rheumatology in Chicago, finds that many lupus patients with low socioeconomic status are unable to attend scheduled appointments with physicians due to daily obstacles.

Successful Pregnancy Outcomes For Most Women With Lupus Promising research led by investigators at Hospital for Special Surgery may offer hope for women with lupus who once thought that pregnancy was too risky.Results from the multicenter National Institutes of Health (NIH) funded PROMISSE initiative, being presented Monday, Nov

Lupus Plus Shortness of Breath: Don't Miss This Diagnosis A 27-year-old African American woman with systemic lupus erythematosus (SLE) of 5 years' duration presents to her rheumatologist for evaluation of shortness of breath that started 3 weeks ago.

XToll Completely Prevented Cutaneous Lupus In Animal Study CBio Limited have announced the publication of their animal trial on the advanced access site of the Oxford Journals publication, Nephrology Dialysis Transplantation. The research is titled - "Recombinant chaperonin10 (Xtoll) suppresses cutaneous lupus and lupus nephritis in MRL-(Fas)lpr mice.

A Simpler System Would Make It Easier For Clinicians To Treat Kidney Problems In Lupus Patients The current classification system for kidney complications in patients with lupus is too detailed, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

Statins Disappoint In Atherosclerosis Progression In Children With Lupus According to the American College of Rheumatology (ACR) 322,000 adult Americans are affected by systemic lupus erythematosus (SLE) with approximately 5,000 to 10,000 children in the U.S. affected by lupus (Lehman 1996), although exact figures for pediatric SLE cases remain difficult to establish.

Long-Term Impairments of Functioning in Obese Women with Lupus Relatively few studies have been conducted about the role and effects of obesity in the lives of people with lupus. Obesity is associated with disability, both in the general population and among people with lupus. Since up to half of people with lupus may be obese, it is important to determine to what extent specific functions (such as walking or climbing stairs) are impaired in people with lupus. Identification of preventable risk factors for disability, such as obesity, has the potential to decrease the negative effects of obesity on functioning in people with lupus.

Variable Effects of Two Influenza A (H1N1) Vaccinations in People with Lupus Most of the world�s population had little or no pre-existing immunological protection against the 2009 influenza A (H1N1) pandemic. People with lupus were considered to be at especially high risk and were recommended for vaccination. Relatively little is known, however, about the effects of influenza vaccinations in people with lupus. This vaccination had variable effects in people with lupus and depended on their white blood cell count and on whether they were taking immune-suppressing drugs. The results highlight the importance of acquiring increased knowledge about and perhaps developing additional strategies for vaccinating people with lupus against influenza A (H1N1).

Genetic Profiling Can Predict Some Lupus Manifestations People with lupus can experience a wide variety of disease-related manifestations, including nephritis (kidney inflammation) and skin rashes. The variability of these symptoms likely results from underlying genetic factors. While most studies have focused on identifying the presence of specific genes that increase the risk of developing lupus, few studies have focused on which genes may give rise to which manifestations of lupus. Identification of which genes may be associated with which lupus manifestations could help facilitate the future development of personalized medicine for people with lupus.

NYC Walk with Us to Cure Lupus First Lupus Walk in History to Raise $1 Million On Saturday, October 22nd the Alliance for Lupus Research (ALR) held our 8th annual New York City Walk with Us to Cure Lupus. The beautiful weather at Battery Park was matched by the enthusiasm of the nearly 3000 walkers in attendance to walk for the cure. The walkers were joined by NYC master of ceremonies, My9 news anchor Brenda Blackmon, ALR Chairman Robert Wood Johnson IV, and Walk Co-chairs Frank Bisignano, Chief Administrative Officer JPMorgan Chase; Daniel LaVecchia, Executive Managing Director BGC Partners; and Mark Wagar, President & CEO Empire BlueCross BlueShield. Spoken poet Shanelle Gabriel inspired the crowd with �Vanity�, her moving personal account of life with lupus.

$8 Million Bloomberg Grant Launches Search for Fundamental Causes Driving to a Cure The Lupus Research Institute (LRI) launched a major international initiative aimed at attracting the highest level scientists to conduct pioneering research to discover the fundamental root causes of lupus, explore the potential for a cure, and transform the field of lupus research. LRI president Margaret Dowd announced the new Distinguished Innovators program amid the nation�s foremost scientists gathered at the 11th annual Lupus Research Institute Scientific Conference, �Forum for Discovery.�

Self-Reported Effects of Cutaneous Lupus on Quality of Life Ultraviolet radiation from the sun can worsen symptoms of cutaneous lupus (CLE). �Photosensitivity� describes a variety of reactions to sun exposure in CLE patients and, accordingly, CLE patients may be described as being more or less �photosensitive� or not at all. However, the reported prevalence of photosensitivity among CLE patients varies widely due to a number of factors related to its measurement.

First-Time Guidelines for Lupus Nephritis: Biopsy for All The first guidelines ever developed for the management of lupus nephritis recommend that physicians biopsy all patients who present with clinical evidence of active disease, classify the disease stage according to the International Society of Nephrology/Renal Pathology Society classification system, and manage the disease on the basis of this classification.

Video Game Can Reduce Fatigue in African-American Women With Lupus Lupus affects many more women than men and many of these women are African-American. Over 80% of people with lupus experience clinically significant levels of fatigue that can disrupt normal daily activities. This fatigue is not necessarily due to use of medications for lupus or to inflammation.

New Experimental Molecule Neutralizes Lupus Autoantibodies�Lupus in humans and animals is marked by production of autoantibodies (antibodies against one�s self) that can cause inflammation, as well as damage components of cells (such as double-stranded DNA or cardiolipin) of one�s own body. In particular, antibodies to double-stranded DNA (ds-DNA) contribute to organ damage.

Women with Lupus Have Decreased Risk for Certain Cancers Cancer risk in lupus is an important topic. Little attention has been focused on women's cancers, even though lupus affects mostly women. Up to now, there have been relatively few studies of the development of these cancers in women with lupus. In this study, the researchers aimed to estimate the risk of breast, endometrial, and ovarian cancers in women with lupus relative to that for the general population.

Comparison of Lupus Nephritis Classifications of Two International Organizations Kidney involvement occurs in about 60% of people with lupus and is a major determinant of long-term disease outcome. The World Health Organization (WHO) published multiple versions of their classifications for lupus nephritis from 1975-2001, but they had several limitations. In 2004, the International Society of Nephrology-Renal Pathology Society (ISN-RPS) revised the WHO classifications for lupus nephritis. The researchers aimed to determine the effects of the ISN-RPS re-classifications for lupus nephritis on patient outcomes

Lack of Cardiovascular Risk Assessment in a Canadian Population of Lupus Patients People with lupus have an increased risk of heart disease and stroke due to premature hardening of the arteries. This increased risk is due in part to traditional risk factors and in part due to lupus-specific immune dysfunction. The researchers aimed to evaluate how effectively risk for heart disease was being assessed in a population of lupus patients being cared for in Alberta, Canada.

The U.S. Department of Defense Awards $2.3 Million in Funding for Lupus Research The Lupus Foundation of America (LFA) Congratulates Trine Jorgensen, Ph.D., Cleveland Clinic Foundation and I-Cheng Ho, M.D., Ph.D., Brigham and Women�s Hospital.

Continued Treatment For Lupus May Boost Survival Of Those Patients With End-Stage Kidney Disease Researchers at Albert Einstein College of Medicine of Yeshiva University have shown that close supervision by rheumatologists and the use of immunosuppressant drugs improve the survival of lupus patients with end-stage kidney disease a finding that could reverse long-standing clinical practice.

OMRF Completes African American genetic study Researchers have long known that lupus strikes African-Americans at a disproportionately high rate. Now, in the most comprehensive genetic study to date of this group, Oklahoma Medical Research Foundation scientists have found evidence linking the disease in African-Americans to five genes.

New fat-derived stem cell treatment restores Lupus body functions Lupus is a tenacious autoimmune disease, affecting about 1.4 million people in the U.S. Considered a high risk disease for mortality and organ damage, a recent study has discovered that fat-derived stem cells can restore lupus to normal body functions.

Migraines are not a lupus symptom: study Despite a commonly-held belief among many doctors who treat lupus patients, headaches -- particularly migraines -- are not a manifestation of that disease and should be treated as a separate problem, report researchers in Greece.

Gender Difference In Autoimmune Disease Explained By Newly Discovered B Cells Researchers at National Jewish Health have discovered a type of cell that may contribute to autoimmune disease. The findings also suggest why diseases such as lupus, multiple sclerosis and rheumatoid arthritis strike women more frequently than men.

Vitamin D Deficiency Among Systemic Lupus Erythematosis Patients Researchers have just found that vitamin D levels among systemic lupus erythematosis (SLE) patients directly relates to the severity of the disease and the development of the infection. The study found that people with low levels of vitamin D are more prone to develop SLE than those with higher levels.

Glaxo's Revolutionary Lupus Treatment Benlysta Now EU Approved The first treatment developed for lupus in over 50 years has finally been approved by the European Union this week. The watchdog, European Medicines Agency, has backed the injectable drug that will cost Europeans $23,000 USD a year.

Scientists Develop a Unique Small Molecule that Neutralizes Lupus Autoantibody Activity A decade ago, Betty Diamond, MD, a lupus investigator at The Feinstein Institute for Medical Research, identified auto-antibodies in the brains of patients with Systemic Lupus Erythematous (SLE) and realized at the time that these auto-antibodies could be a potentially important target for drug development.

Father and son ride 100 miles to raise funds for lupus research On Saturday, June 4, Dr. Charles Huebner, 57, of Petoskey, and his 21-year-old son, Christian, lined up their bicycles in Suttons Bay, northwest of Traverse City. The father-son duo have been riding bikes together for years, but this wasn�t an ordinary ride. From Suttons Bay, Charles and Christian rode a path that took them 100 miles all the way to Petoskey. It was all in an effort to raise money for lupus research.

Man Runs 70 Miles Along M-22 for Lupus Cure Call it running - a very long way - for a cause. June 4th, a 5k walk was held for Lupus research in Frankfort, MI. But one man has decided to take things to a whole new level - by running 70 miles along M-22 from Suttons Bay to Frankfort.

Study Of African-American Women Reveals New Genetic Risk Factors Of Lupus Researchers from Boston University's Slone Epidemiology Center have found four new genetic variants in the major histocompatibility complex (MHC) that confer a higher risk of systemic lupus erythemathosus ("lupus") in African American women.

Advances in Understanding Pregnancy and Lupus Not very long ago, doctors would often advise their female patients with lupus not to become pregnant because of the risks to both mother and unborn child � heartbreaking news for anyone who wanted to have children. But that was 20 years ago, and thankfully much progress has since been made in the scientific understanding of the disease. In the last decade, the Alliance for Lupus Research (ALR) has been able to add its contributions to this growing body of knowledge. Intensive studies of pregnancy and lupus have yielded impressive results � which, in turn, increase the potential for future advances.

Belimumab Shows Sustained Benefits in SLE Six years of follow-up confirm the benefits of belimumab reported in phase 3 trials of systemic lupus erythematosus (SLE), according to the results of an open-label study announced here at the European League Against Rheumatism Congress 2011.

Survey Reveals Lupus' Ability To Wreck Careers Lupus has a profoundly negative effect on the working lives of sufferers', found a survey of over 2,000 lupus patients presented at the Annual Meeting of the European League Against Rheumatism (EULAR) in London, May 25-28.

Disease Activity In Systemic Lupus Erythematosus Patients Not Increased By The HPV Vaccine Gardasil Results of a Chinese study showed that the HPV vaccine did not have significant effects on the number of disease flares or antibody measures in patients with inactive SLE receiving stable doses of medications after administration, and therefore was determined safe to use to prevent HPV in this group of patients. SLE, an autoimmune disorder, affects nine times as many women as men1 and studies have shown that the rate of HPV in this group is significantly higher than in the healthy population.2 Vaccination is therefore an important consideration in protecting SLE patients from HPV infection, which has been shown to be responsible for cervical cancer.

Results Showed 7 Out Of 10 Patients Reported That Lupus Affected Their Careers LUPUS EUROPE (LE) and UCB today announced results from the pan-European Lupus European Online (LEO) survey, believed to be the first online survey of its kind completed by lupus patients using validated measures assessing the impact of lupus. These patient-reported outcome (PRO) measures included assessments of fatigue, work impairment and health-related quality of life

EULAR 2011 - Vidofludimus Superior To Cyclophosphamide And MMF In An Experimental SLE Model 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune and cancer diseases, will present pre-clinical data on vidofludimus - its lead small-molecule drug candidate against autoimmune diseases - in systemic lupus erythematosus (SLE) at EULAR 2011, Europe's largest scientific conference on rheumatic diseases, in London, UK, from May 25-28, 2011.

GSK Lupus Treatment Benlysta Reaches Europe After US Approval The first treatment developed for lupus in over 50 years has been reocommended for approval by the European Union this week. The watchdog, European Medicines Agency has backed the injectable drug that will cost Europeans $23,000 USD a year. Already approved in the United States in March 2011, the drug costs Americans $35,000 USD annually.

Black Americans With Lupus Have Better Response to Flu Vaccine Black Americans with lupus have a higher antibody response to flu vaccination than whites with lupus, a new study says. This may be good news for black Americans with the disease, since patients who had a weak response to the flu vaccine were more likely to experience moderate to severe disease flares following vaccination, compared to patients who had a greater response.

New Technique To Duplicate Immunity Boosting Cells Will Benefit Transplant & Autoimmune Patients University of Minnesota Medical School researchers have discovered a method to quickly and exponentially grow regulatory T-cells - also known as "suppressor cells." The new process enables replication of the cells by tens of millions in several weeks, a dramatic increase over previous duplication methods.

New Test Could Give SLE Patients A More Tolerable Life "At present, it can take up to a year before a patient is diagnosed with SLE. This is because the symptoms are diffuse and are often mistaken for other diseases. However, with this blood-based test, it is possible to determine quickly whether someone has the disease or not", says Christer Wingren, associate professor in Immunotechnology at CREATE Health, Lund University.

Novel Pathophysiologic Mechanism Responsible For Autoimmunity Identified By Scientists Researchers from Boston University School of Medicine (BUSM) have discovered that human proteins with an affinity for Dermatan Sulfate (DS) have the propensity to become autoantigens. In a companion article, the researchers also found that DS physically interacts with dead cells and that the resulting DS-autoantigen complexes drive autoreactive B-1a cell responses and autoantibody production both in-vitro and in mouse models.

Exposure to Insecticides May Up Autoimmune Disease Risk Women who are exposed to insecticides at home or in the workplace have an increased risk of rheumatoid arthritis (RA), or systemic lupus erythematosus (SLE), according to a study published in the February issue of Arthritis Care & Research

Diabetes and Disease Activity Predict Depression in Lupus Diabetes mellitus and systemic lupus erythematosus (SLE)-related disease activity appear to increase the likelihood of developing depression in SLE, according to a study published in the April issue of Arthritis Care & Research.

Discovery Of Relationship Between Proteins May Impact Development Of Autoimmune Therapies By identifying a surprising association of two intracellular proteins, University of Iowa researchers have laid the groundwork for the development of new therapies to treat B cell lymphomas and autoimmune disease.

Lupus Foundation Of America And RN.com Launch New Lupus Education Program The Lupus Foundation of America (LFA) announced today the launch of a new continuing education program entitled, Lupus, Deciphering the Clues, co-developed with RN.com and RxSchool.com, and Dr.

Study Of Umbilical Cord Blood-Derived Stem Cells For Lupus Therapy Human umbilical cord blood-derived mensenchymal stem cells (uMSCs) have been found to offer benefits for treating lupus nephritis (LN) when transplanted into mouse models of systemic lupus erythematosus (SLE).

Findings Reported On The Impact Of Autoimmune Diseases On Taste Scientists supported by the National Institute on Deafness and Other Communication Disorders (NIDCD), one of the National Institutes of Health, will be presenting their latest research findings at the 2011 Annual Meeting of the Association for Chemoreception Sciences (AChemS).

S.L.E. Lupus Foundation Announces New Grants To Further NYC Scientists' Leadership In Lupus Research New York City's S.L.E. Lupus Foundation is pleased to name the latest recipients of its Career Development and Basic Science Fellowships: Josephine Isgro, MD of Hospital for Special Surgery (HSS), Dipyaman Ganguly, PhD of Columbia University Medical Center, and Yi Yan, PhD of the Feinstein Institute at North Shore-Long Island Jewish (LIJ) Hospital.

Who Should Get Belimumab? On March 9, 2011, the US Food and Drug Administration approved belimumab, or Benlysta�, for the treatment of SLE. This represents the first time in more than 50 years that a drug has been approved for the treatment of SLE, but is it right for all SLE patients?

Changes In Incidence Of End-Stage Renal Disease From Lupus Nephritis But No Outcome Improvement In Over a Decade New research documenting changes in the incidence and outcomes of end-stage renal disease (ESRD) in the U.S. between 1995 and 2006, found a significant increase in incidence rates among patients 5 to 39 years of age and in African Americans.

Scientists Discover Genetic Changes That May Predispose Women To Preeclampsia Scientists have discovered genetic defects that appear to predispose women to a common pregnancy-related medical problem called preeclampsia that can threaten the life of both baby and mother.

Nonadherence to Medications Common in Lupus Patients In patients with systemic lupus erythematosus, intentional and unintentional nonadherence are commonly reported, according to a study published in the March issue of Arthritis Care & Research.

New Lupus Therapy Approval Coincides With Autoimmune Diseases Awareness Month According to Virginia T. Ladd, President and Executive Director of the American Autoimmune Related Diseases Association (AARDA), "The FDA's approval of Benlysta is momentous not only for the new hope it brings to the 300,000 to 1.5 million Americans suffering with lupus but also for the millions of Americans who suffer from many other autoimmune diseases such as autoimmune hemolytic anemia and autoimmune hepatitis. These diseases, along with lupus, have not seen the development of specific new treatments since the 1950s. Benlysta exemplifies a welcomed interest by today's biotechnology and pharmaceutical companies to investigate and develop new treatments for orphan and less common diseases."

FDA Approves Benlysta To Treat Lupus The U.S. Food and Drug Administration approved Benlysta (belimumab) to treat patients with active, autoantibody-positive lupus (systemic lupus erythematosus) who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives, and nonsteroidal anti-inflammatory drugs.

Should Belimumab Have Been Approved? Response from Stephen Paget, MD Professor of Medicine, Weill Cornell Medical College; Physician-in-Chief, Center for Rheumatology, Hospital for Special Surgery, New York, NY In my opinion, belimumab was approved for the following reasons:

LRI awards grants to drive next generation of scientific discovery in lupus Commits $3.6 million for innovative studies to find new solutions for devastating disease with limited treatment options. The Lupus Research Institute (LRI) today announced the award of 12 new research grants, building on its decade-long commitment to drive innovation and discover novel approaches to understand and treat one of the world's most confounding and elusive diseases � lupus.

San Antonio researcher tapped for major Lupus study The Lupus Research Institute on Tuesday awarded a $300,000 research grant to University of Texas Health Science Center at San Antonio researcher Tyler Curiel where he will explore possible scientific causes for the disproportionately high prevalence of lupus in women.

Exposure to Insecticides May Up Autoimmune Disease Risk Women who are exposed to insecticides at home or in the workplace have an increased risk of rheumatoid arthritis, or systemic lupus erythematosus, according to a study published in the February issue of Arthritis Care & Research.

Advocates Seek Increased Federal Funding to Bridge the Gaps in Lupus Research, Awareness, and Education On Tuesday, March 1, 2011, nearly 200 advocates from across the country will band together for lupus and urge Members of Congress to support increased federal funding to bridge the gaps in lupus research, awareness, and education during the Lupus Foundation of America�s (LFA) Thirteenth Annual Advocacy Day in Washington, DC.

Earlier Rituximab Better for Lupus Nephritis Patients Lupus nephritis patients who receive rituximab earlier in the course of their disease rather than later have better outcomes, new findings suggest.

Idera Pharmaceuticals Presents Data On IMO-3100 in Lupus Showing Suppression Of Disease Progression Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that it is presenting data on IMO-3100, an antagonist of TLR7 and TLR9, in a preclinical model of lupus showing that treatment with IMO-3100 suppressed several key disease progression parameters.

Assessing the Cost of Lupus If you have lupus, you don�t need a study to tell you that the disease is expensive. Even with the best health insurance, you�re likely spending thousands of dollars out of pocket each year for doctor visits, medications, and other health-related costs. And that doesn�t even count the cost to your work and income.

Risk of Some Cancers Double in Lupus Previous research has shown a link between lupus and certain cancers, particularly lymphoma. To determine whether there is actually an increased risk of cancer in patients with lupus, Sasha R. Bernatsky, MD, PhD, of McGill University in Montreal, and her colleagues analyzed data from more than 13,000 people from 24 lupus centers around the world followed for an average of 9 years. They found an overall 15% increased risk of cancer, but a more than doubled risk of blood-related cancers such as lymphoma, non-Hodgkin�s lymphoma, and leukemia.

Treatment May Help Prevent Neonatal Lupus Exciting news for women at risk of delivering a child with neonatal lupus. A study presented at the ACR meeting found that women who took hydroxychloroquine (Plaquenil�) during their pregnancy reduced their risk of having a child with the cardiac form of the disease by 75% and the risk of any form of the disease (cardiac or cutaneous) by 44%.

HGS & GSK Announce Publication Of Study Results For BENLYSTA(R) In The Lancet Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced publication of the BLISS-52 study of BENLYSTA� (belimumab) in autoantibody-positive patients with active systemic lupus erythematosus (SLE) in The Lancet.

J. Dilla Documentary Released to Commemorate Birthday In celebration of legendary producer J. Dilla's 37th birthday today, a documentary has been released about the revered former A Tribe Called Quest and Slum Village producer. The 39-minute film, entitled 'Still Shining,' covers the life of the gifted Detroit producer and rapper, who died of lupus on Feb. 10, 2006, just days after turning 32.

New clue to lupus: Failed autoimmune suppression mechanism Researchers at Dana-Farber Cancer Institute in Cambridge, Mass., in collaboration with Jackson Laboratory scientists, have identified a regulatory defect that drives lupus.

Research Uncovers Key To Understanding Cause Of Lupus Potentially impacting future diagnosis and treatment of lupus, an immune illness affecting more than 5 million people worldwide, researchers at the Virginia-Maryland Regional College of Veterinary Medicine at Virginia Tech have likely uncovered where the breakdown in the body's lymphocyte molecular regulatory machinery is occurring.

Lupus Foundation Of America Expands Services With Launch Of New Education Series The Lupus Foundation of America (LFA) has launched a new nationwide education series, Lupus: Learn from the Experts,� designed to provide people with lupus essential information about living with lupus from some of the world's leading lupus experts.

Link To Increased Atherosclerosis Risk In Lupus Patients Revealed By Researchers Researchers in China have demonstrated interferon-alpha (IFN-a) is associated with increased risk of atherosclerosis in patients with systemic lupus erythematosus (SLE). For the first time, IFN-a priming was shown to promote lipid uptake and foam cell formation - a crucial step in plaque build-up.

Hydroxychloroquine Scores Big in Lupus The past 12 months have brought a slew of studies making a persuasive case for hydroxychloroquine as a far more important drug in lupus than previously thought. Indeed, the drug could now even be considered essential. "In 2011, all lupus patients should receive hydroxychloroquine," Dr. David Wofsy flatly declared at a symposium sponsored by the American College of Rheumatology.

Study isolates 'master switch' for macrophages in inflammation prevention A new study has identified a potential method of controlling the behaviour of macrophages that could prove beneficial in combating inflammatory diseases.

Patent awarded for method to dampen immune response National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants. This therapeutic approach has the potential advantage of inactivating B cells instead of killing them as current treatments do. Therefore, this potential therapy could be more rapidly adjusted in response to the changing needs of patients.

Sunscreen May Prevent Lesions in Photosensitive CLE Patients Use of a broad-spectrum sunscreen may prevent skin lesions in photosensitive patients with cutaneous lupus erythematosus, according to research published in the January issue of the Journal of the American Academy of Dermatology.

FDA Limits Ingredient in Popular Lupus Painkillers The U.S. FDA says it's asking the makers of combination painkillers to limit the amount of acetaminophen the drugs contain and to start including warning labels about the dangers of liver damage. Acetaminophen is the drug in Tylenol.

Anthera Resumes Trial Testing On Lupus Patients While Starting On Other New Trials Piper Jaffray has published a research report on Anthera Pharmaceuticals (NASDAQ: ANTH) after the company resumed patient screening for its Phase IIb PEARL-SC lupus trial of A-623. In the report, Piper Jaffray writes "Anthera has resumed patient screening in the Phase IIb PEARL-SC lupus trial of A-623. Dosing of patients should recommence by the end of the month.

Lupus Foundation Of America Achieves International Consensus On Definition Of A Lupus Flare The Lupus Foundation of America (LFA) spearheaded a four-year worldwide initiative with more than 120 lupus experts from 11 countries, the pharmaceutical and biotechnology industries, and federal agencies, which resulted in the first-ever global definition of a lupus flare.

Higher Risk for Blood Clots Found in Hospitalized Arthritis Patients Patients with certain immune diseases (like rheumatoid arthritis, systemic lupus erythematosus, polyarteritis nodosa and others) have an increased risk of developing venous thromboembolism during hospital stays, according to research published January 10, 2011 in BMC Medicine. Venous thromboembolism includes deep vein thrombosis (often referred to as DVT) and pulmonary embolism. The increased risk was found after researchers at the University of Oxford analyzed patient records that were collected over a 45-year period.

New research finds pattern for detecting 'false-positive' ANA results The presence of antinuclear antibodies (ANA) indicates the possibility of autoimmunity and the indirect immunofluorescence (IIF) assay on HEp-2 cells is the standard blood test (ANA-HEp-2) used to detect ANA. However, studies have shown that a "false-positive" ANA test occurs in up to 13% of healthy individuals. In such cases the test detects the presence of autoantibodies that apparently are not associated with autoimmunity. Researchers from Brazil have now uncovered distinguishing characteristics of the ANA test in healthy individuals and patients with autoimmune disease, reducing the likelihood of an erroneous autoimmune disorder diagnosis. Their findings are published in the January 2011 issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

Use of Hydroxychloroquine Benefits Sugar Metabolism in Women With Lupus Hydroxychloroquine (Plaquenil) is in a class of drugs that was originally developed to treat malaria and has been considered to be a safe and effective treatment for mild lupus and rheumatoid arthritis (RA) since 1957. Low blood sugar is an occasional side effect of taking these anti-malarial drugs, but how this happens is not well understood.

Unexpected Role In Lupus Played By Immune Cell A new study provides fascinating insight into the underlying pathology associated with the autoimmune disease, systemic lupus erythematosus (SLE). The research, published by Cell Press in the December issue of the journal Immunity, reveals an unexpected role for a key type of immune cell and provides a potential new therapeutic strategy for SLE and, potentially, other autoimmune diseases.

Children with Lupus Have More Lethal Form of Kidney Disease Kidney disease caused by the autoimmune disease lupus may be twice as lethal in children as kidney disease caused by other disorders, according to research led by Johns Hopkins Children�s Center investigators.

Julian Lennon adds commitment to lupus charity with new title of patron Julian Lennon has joined the St. Thomas� Lupus Trust as a patron to help raise funds and awareness about the disease, the organization announced Tuesday.

Argos Therapeutics Initiates Dosing of Patients in Phase 1 Clinical Trial of Therapy for Treatment of SLE Argos Therapeutics today announced that it has initiated dosing of patients in a Phase 1 clinical trial of its monoclonal antibody-based therapy, AGS-009, for the treatment of systemic lupus erythematosus (SLE). AGS-009 is a humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with the ability to bind and neutralize human interferon alpha (IFN-alpha).

SuppreMol Wins $2.1M Funding for Clinical Development of Lupus Therapy SuppreMol has been awarded �1.6 million ($2.1 million) in research funding from the German Federal Ministry of Education and Research (BMBF) to support further development of its lead clinical candidate, SM101. The grant will be used partly to support early clinical evaluation of SM101 against systemic lupus erythematosus (SLE), and particularly the lupus nephritis subform of the disease. It will also help fund preclinical evaluation of SM101 in animal models of chronic obstructive pulmonary disease (COPD).

Marijuana use suppresses immune functions, study shows Smoking marijuana can trigger a suppression of the body�s immune functions, making cannabis users more susceptible to certain types of cancers and infections, according to a new study led by a University of South Carolina researcher.

FDA Extension Of Benlysta� PDUFA Target Date To 10th March 2011 GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target date for its priority review of the Biologics License Application (BLA) for Benlysta� (belimumab) as a potential treatment for systemic lupus erythematosus (SLE) from 9th December 2010 to 10th March 2011.

A Major Advance in Use of Steroids Steroids are widely used for a diverse array of medical purposes... including autoimmune diseases. Yet for all of its benefits, this therapy is no cure-all. In fact, it can cause serious internal damage � especially for people with lupus. Today, new findings from an ALR-funded investigation are changing our concept of steroids.

Lupus Foundation Of America President Presents At Women In Government Summit Sandra C. Raymond, President and Chief Executive Officer of the Lupus Foundation of America (LFA) provided an overview on the impact of lupus on women's health to state legislators during the Women in Government's (WIG) first-ever Healthcare Summit in Washington, DC November 18, 2010.

Belimumab Reduces Disease Activity and Corticosteroid Use in SLE A combined analysis of the BLISS-52 and BLISS-76 phase 3 trials showed that belimumab significantly reduced disease activity, severe flares, and corticosteroid use in patients with systemic lupus erythematosus (SLE).

What Is Unique About Early-onset Lupus? It is generally thought that childhood-onset systemic lupus erythematosus (SLE) is more severe than adult-onset disease. A possible explanation for more severe SLE in childhood is that there may be more genetic risk factors present in those with early-onset SLE, with these genes driving both earlier onset of disease as well as more severe manifestations of disease. These authors investigated the relationship of age of onset of SLE, clinical manifestations of disease, and presence/absence of known SLE-susceptibility alleles.

Anthera Suspends Enrollment And Dosing In PEARL-SC Clinical Trial To Address Reports Of Vial Problems Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced that it has notified the US Food and Drug Administration (FDA) that the company has placed a voluntary hold on PEARL-SC, the Phase 2b study of A-623 for the treatment of Systemic Lupus Erythematosus (lupus), due to problems found with product vials.

Lupus Drug Benlysta Gets Thumbs Up From FDA Advisory Panel An FDA Arthritis Advisory Committee voted 13 to 2 in favor of approving Benlysta (belimumab), a lupus medication. The FDA (Food and Drug Administration) Advisory Committee consists of 15 outside experts, their recommendations are not binding, however, the FDA nearly always goes along with what they recommend.

Epratuzumab, New Drug In Development For Systemic Lupus Erythamatosus Enters Phase III Trials For the past 50 years there have been no new drug treatments approved for systemic lupus erythamatosus (SLE). Now, at last, that situation could soon change. The FDA is currently reviewing one new drug whilst another, epratuzumab, in development by Immunomedics Inc and UCB, is about to start phase III clinical trials after showing promising results in a smaller trial.

New Assessment Tool Helps in the Worldwide Analysis of Lupus in Kids Research presented at the American College of Rheumatology (ACR) annual meeting, held Nov. 7-11, in Atlanta sheds light on a newly designed tool, which is helping researchers shed light on the quality of life (QoL) of children with lupus around the world.

General Pediatric Lupus Population Does Not Benefit From Statins Lupus puts children at higher risk for coronary artery disease when they become adults, but routinely using statins doesn't provide enough benefit to warrant their regular use in children and adolescents, according to the largest study of pediatric lupus patients to date.

Penn Scientists Identify New Role for Protein Molecule That Inhibits Response of Immune-System Cells Researchers at the University of Pennsylvania have identified a new role for a protein molecule that inhibits the response of immune-system cells to inflammatory signals associated with many human diseases.

Researchers Find Clue to Preventing Heart Complications Associated with Neonatal Lupus Women with anti-SSA/Ro antibodies and a previous child who has heart block�a condition where the electrical signal that makes the heart beat is damaged�may potentially decrease their risk of delivering another child with life threatening heart disease by taking hydroxychloroquine (Plaquenil�), according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

F.D.A. Panel Backs Drug for Lupus What could become the first new drug approved to treat lupus in more than half a century moved a big step closer to the market on Tuesday by winning an endorsement from a federal advisory committee.

We've Come A Long Way, Researchers, How A Decade Of Research Is Helping Lupus Patients Today, individuals with lupus nephritis benefit from better treatments than a decade ago, according to a review appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

Lupus Antibodies Related to Persistent Disease Activity and Heart Disease The researchers hoped to learn whether antibodies to cholesterol regulators are associated with disease activity or heart disease in people with lupus. The antibodies studied are called anti-apolipoprotein A-I (anti-Apo A-I), anti-high-density lipoprotein (anti-HDL), and anti-C-reactive protein (anti-CRP).

Low Levels of Vitamin D Are Seen With Increased Lupus Disease Activity The researchers hoped to learn about the relationship between levels of vitamin D in the blood and lupus disease activity.

Hydroxychloroquine and glycemia in women with SLE The researchers hoped to learn whether there are any tests that could predict low blood sugar in women with lupus taking hydroxychloroquine.

LFA Advances Clinical Research With Launch Of New Online Registry People with lupus nationwide can now sign up to be notified of local clinical studies enrolling volunteers through the Lupus Foundation of America's (LFA) Center for Clinical Trials Education (CCTE).

Questions Remain About Abatacept Lupus Trial Abatacept (Orencia; Bristol-Myers Squibb) did not prevent new lupus flares in a phase 2b study of patients tapered from corticosteroids, and the study also did not meet secondary endpoints, but problems with the study design mean that abatacept should not yet be counted out as a drug for the treatment of systemic lupus erythematosus (SLE).

The Lupus Foundation Of America Congratulates Dr. John Harley On $1.1 Million Award From The Department Of Defense For Lupus Research The Lupus Foundation of America, Inc. (LFA) congratulates John Harley, M.D., Ph.D., Director of Rheumatology, Cincinnati Children's Hospital Medical Center, who has received a $1.1 million research grant from the U.

University of Minnesota licenses lupus test to LabCorps The University of Minnesota has licensed a test for lupus to Laboratory Corporation of America Holdings (NYSE:LH). Developed by Emily Baechler Gillespie, an assistant professor of medicine at the university�s medical school, the test can help doctors proactively treat symptoms of lupus, a painful autoimmune disease.

Cutaneous Lupus Linked to Increased Skin Cancer Risk Patients with cutaneous lupus erythematosus appear to have an elevated overall risk of cancer, especially nonmelanoma skin cancer, lung cancer, and non-Hodgkin's lymphoma.

New Grants Fund Critical Areas Of Lupus Research The Lupus Foundation of America, Inc. (LFA) today announced the awarding of six new research grants to address gaps in the science and understanding of key areas of lupus research, including pediatric lupus, reproductive health issues in people with lupus, lupus nephritis (kidney involvement), and neuropsychiatric lupus, which affects the brain and nervous system.

Cutaneous Lupus Rapidly Progresses to SLE, New Study Finds Rapid progression of cutaneous lupus erythematosus to SLE occurs considerably more often than previously recognized, a comprehensive nationwide Swedish study found.

Lupus Research Investigator Says Breakthrough Holds Potential For New Treatment To Quiet Lupus Researchers at the Dana-Farber Cancer Institute in Boston have identified a new type of cell in mice that dampens the immune system and protects the animal's own cells from immune system attack.

Jets luncheon raises nearly $1M for pair of charities The New York Jets on Wednesday raised an unprecedented amount of money for two of the team�s charities at an event in lower Manhattan that drew Garden State business owners and Gov. Chris Christie. The season kickoff luncheon raised nearly $1 million for the Alliance for Lupus Research and the Jets Foundation.

Proteins on Blood Cells More Accurately Predict Lupus Disease Activity The researchers hoped to learn whether measurement of C3d and C4d would be a more accurate way to test for lupus disease activity when measured while attached to a red blood cell than when they are freely circulating in the blood.

Pregnancy Outcomes in Women with Lupus Nephritis The researchers hoped to determine the specific effects of active lupus-related kidney disease (lupus nephritis or LN) on pregnancy outcomes, as well as complications that might occur in the mothers or babies.

Brain Involvement in an International Cohort of Lupus Patients The researchers hoped to accurately determine the frequency and outcome of �neuropsychiatric lupus� (NPL) (brain inflammation), as well as its impacts on quality of life. This ongoing study will follow people with newly diagnosed lupus over 10 years. This paper is an early report of this study.

Abatacept Found Ineffective In Treatment Of Non-Life Threatening Lupus Results from a 12-month multi-center clinical trial did not show therapeutic benefit of abatacept over placebo in patients with non-life threatening systemic lupus erythematosus (SLE). Abatacept failed to prevent new disease flares in SLE patients tapered from corticosteroids in an analysis where mild, moderate and severe disease flares were evaluated together.

Human Genome Sciences readies Lupus drug ahead of FDA approval Human Genome Sciences Inc. is racing to manufacture the first stockpile of its now-flagship lupus drug candidate, Benlysta, recruiting a small army of sales reps and ramping up a national marketing campaign nearly three months before its anticipated federal approval decision date.

Scientists identify the class of cells T-cells CD8 + which will help combat diseases like Lupus Scientists have identified a class of cells in mice, which determines the activity of their immune system against the pathogenic cells and the cells of their own tissues. The opening will lead to new methods of combating cancer and autoimmune diseases in humans, according to the journal Nature.

Promise of new immune system-based therapies detailed in new studies. Dana-Farber Cancer Institute scientists have identified cells in mice that prevent the immune system from attacking the animals' own cells, protecting them from autoimmune diseases such as multiple sclerosis, type 1 diabetes, and lupus.

Glaxo and Genmab drop IV version of immune drug GlaxoSmithKline PLC and Genmab A/S will end the development of an intravenous form of a drug intended to treat autoimmune diseases like lupus and multiple sclerosis, and focus on an injectable version.

Discovery highlights promise of new immune system-based therapies A new focus on the immune system's ability to both unleash and restrain its attack on disease has led Dana-Farber Cancer Institute scientists to identify cells in mice that prevent the immune system from attacking the animals' own cells, protecting them from autoimmune diseases such as multiple sclerosis, type 1 diabetes, and lupus.

Molecular Gatekeeper Of Arthritis Identified Elimination of a molecular gatekeeper leads to the development of arthritis in mice, scientists report in a study published in The Journal of Experimental Medicine. The newly discovered gatekeeper is a protein that determines the fate - survival or death - of damaging cells that mistakenly attack the body's own tissues and lead to autoimmune disorders such as arthritis.

Epigenetic Mechanisms in Lupus Epigenetic mechanisms regulate gene expression, and epigenetic gene dysregulation is implicated in the pathogenesis of a growing number of disorders. Of the autoimmune diseases, epigenetic mechanisms are most clearly involved in human systemic lupus erythematosus (SLE). Herein, we summarize earlier work on epigenetic mechanisms contributing to human SLE. We first focus on the roles of DNA demethylation and DNA methyltransferase enzyme dysregulation, and we then review recent and important advances in this field.

First Direct Evidence that X-Linked TLR7 Gene Promotes Lupus in Humans Lupus Research Institute-funded researcher Betty Tsao, PhD, at the University of California Los Angeles has discovered that humans�males in particular�with a variant form of the immune receptor gene "Toll Like Receptor 7 (TLR7)" are at increased risk of developing the autoimmune disease systemic lupus erythematosus (lupus). This breakthrough finding offers renewed hope for developing more targeted treatments.

Overactive Blood Platelets May Play Role in Lupus Overactive blood platelets could trigger inflammation in those with lupus, but the anti-clotting drug Plavix might ease the painful symptoms of this autoimmune disease, a new study suggests.

Academy to issue new guidelines for hydroxychloroquine retinopathy screening Updated guidelines for managing patients on hydroxychloroquine therapy will emphasize the careful monitoring with imaging of patients on therapy longer than 5 years.

Biologics in the Treatment of Systemic Lupus Erythematosus The pathogenesis of systemic lupus erythematosus (SLE) involves aberrancy in multiple components of the immune system including B cells, T cells, cytokines and growth factors. Therapeutic agents targeting these mediators selectively have been tested for the treatment of SLE. This review summarizes the recent advances in the fast expanding field of these biological therapies.

Lupus Researchers Will Examine Ways To Best Apply Findings From Lupus Mouse Model To Human Lupus Nearly 200 lupus researchers, clinicians and representatives from government, industry, academia and nonprofit organizations involved in lupus research will gather on the campus of the National Institutes of Health to look at ways to best apply research findings from lupus mouse models to human lupus.

EULAR recommendations on neuropsychiatric effects of SLE An expert EULAR panel has developed recommendations on managing the neuropsychiatric manifestations of systemic lupus erythematosus (SLE).

Vitamins influence on genes studied Vitamin D influences more than 200 genes, including some that play a role in serious autoimmune conditions and cancer, a study has shown.

UCLA study identifies genetic variation linked to lupus in Asian men Genes reside along long chains of DNA called chromosomes. UCLA researchers have found that a variation in a gene on the sex chromosome X may enhance an immune response that leads to lupus in men.

Lupus Drug Benlysta� (belimumab) Priority Review Granted By FDA Benlysta� (belimumab), a potential treatment for systemic lupus erythematosus has been granted a priority review designation by the FDA (Food and Drug Administration, USA), which is granted to medications, that if approved, offer significant treatment advances or provide treatment when no proper therapy exists.

Black women with SLE develop cardiovascular disease at early age A recent study by researchers at Penn State College of Medicine found significant racial disparities in the age of systemic lupus erythematosus (SLE) patients at the time of hospital admission for cardiovascular disease (CVD) events and CVD-related death. Black women were youngest to both be admitted with CVD and to have an in-hospital death due to CVD. Results of the study appear in the September issue of Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology.

Modified Systemic Lupus Disease Index Designed An additive scoring system for the BILAG-2004 systemic lupus erythematosus (SLE) disease activity index has been developed and should be useful for statistical analysis of SLE disease data, according to research published in the September issue of Rheumatology.

Research Examines The Biomedical Diagnosis Of Pain Is the science of diagnosing pain causing a number of pain sufferers to defend their honor? Research out of the University of Cincinnati is examining the diagnosis of pain that evades scientific testing, and the additional emotional suffering that can result for the patient

Anti-malarial Drugs Decrease Risk of Blood Clots in People with Lupus Researchers hoped to determine the risk of developing blood clots in people with lupus, while factoring in the year of diagnosis and disease severity.

Hydroxycholoroquine May Protect Against Skin Involvement in Lupus Researchers hoped to learn what factors have an impact on how much time it takes for a lupus patient to develop skin damage.

A Self-Assessed Lupus Organ Damage Instrument Researchers hoped to learn whether a lupus damage questionnaire, filled out by lupus patients instead of their doctors, would be accurate and/or useful.

Human Genome Sciences and Lonza Enter Commercial Manufacturing Agreement for BENLYSTA(R) Human Genome Sciences, Inc. (Nasdaq:HGSI) and Lonza today announced an agreement for the future commercial supply of BENLYSTA(R) (belimumab), which is currently under regulatory review in the United States and Europe as a potential new treatment for SLE.

Boosting vitamin D may ease lupus fatigue People with systemic lupus erythematosus (SLE or lupus) may benefit from taking vitamin D supplements, new research suggests. A team at the University of the Basque Country in Bizkaia, Spain, found that boosting vitamin D levels may help to ease the fatigue experienced by people with lupus, although the intervention does not appear to reduce the severity of the disease itself.

Lupus gene 'protects against malaria' Researchers from the Cambridge Institute for Medical Research and colleagues found that people with two copies of a particular gene variant are more susceptible to developing lupus, but that the same variant also confers increased protection against the malaria parasite.

New Target For Treating Autoimmunity Autoimmune disorders, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), occur when an individual's immune system turns on other cells in the body. Inappropriate and excessive production of the soluble immune mediators IL-17 and IL-21 have been linked to several autoimmune disorders.

Illinois establishes Lupus awareness program CHICAGO � Gov. Patrick Quinn has signed the Lupus Awareness and Education Act into law, establishing a program in the Illinois Department of Public Health to focus specifically on lupus education and awareness throughout the state.

New Drug Target For Immune Diseases Discovered Researchers from Mount Sinai School of Medicine have found a new mechanism that explains how certain immune cells are activated to create protective antibodies against infections or pathological antibodies such as those present in autoimmune diseases like lupus and rheumatoid arthritis.

Anthera initiates Phase IIb Study in Lupus with A-623 Anthera Initiates Expanded and Extended PEARL-SC Phase 2b Clinical Study in Lupus With A-623 - A Subcutaneous Dual Inhibitor of Membrane and Soluble B-Cell Activating Factor (BAFF or BLyS).

Stem Cell Transplant Benefits Severe Lupus Allogeneic mesenchymal stem cell transplantation resulted in improvements in disease activity, serologic markers, and renal function in patients with refractory systemic lupus erythematosus (SLE), a pilot study conducted in China found

Researchers Uncover Biological Rationale for Why Intensive Lupus Treatment Works Researchers at UT Southwestern Medical Center have uncovered the biological rationale for why large doses of corticosteroids given repeatedly over several weeks may help individuals with lupus, a chronic inflammatory disease that affects more than 1 million people in the U.S.

DHEA Treatment for Fatigue in SLE? Effects of Dehydroepiandrosterone on Fatigue and Well-being in Women With Quiescent Systemic Lupus Erythematosus: A Randomized Controlled Trial.

An Exploration Study of Umbilical Cord Stem Cell Treatment in Lupus The researchers hoped to determine whether umbilical cord stem cells could be given safely to people with severe and treatment-resistant lupus, and whether this might help to treat lupus.

HGSI Inks Supply Deal for Benlysta and Switzerland-based company Lonza inked a supply deal for Human Genome�s potential blockbuster lupus drug candidate, Benlysta. The financial clauses of the agreement were not disclosed.

New Research Uncovers Why Many With Lupus Are Resistant To Traditional Treatments Two immune system proteins could be the culprit behind many lupus patients' resistance to widely used steroid treatments, scientists with the Baylor Research Institute (BRI) in Dallas announced today.

FDA Sets Endpoint for Trials Testing Lupus Treatments. Drugmakers developing products for the treatment of systemic lupus erythematosus (SLE) should use a disease activity index such as the British Isles Lupus Assessment Group as the primary efficacy endpoint in clinical trials, the FDA says. Drugmakers also should conduct at least two adequate and well-controlled trials, the FDA says in a final guidance on developing drugs to treat SLE. The preferred design is a parallel, randomized, controlled superiority trial using placebo or active control. In general, the trial should be at least one year in duration.

People With Lupus Denied Health Insurance Due To Pre-Existing Condition May Be Able To Obtain Coverage Through Health Care Reform Law Plan President Obama signed the Health Care Reform package in to law in March 2010, which will extend insurance coverage to as many as 32 million Americans who currently do not have health insurance, as well as provide much-needed protections for people with lupus and other chronic conditions

Antioxidants no help vs rheumatoid arthritis, lupus. Antioxidants in food and supplements might not protect women from rheumatoid arthritis (RA) or lupus after all, a large U.S. study suggests.

Oxidative And Nitrosative Stress Contribute To Lupus Disease Activity University of Texas Medical Branch researchers have uncovered an association between free radical-mediated reactions and the severity and progression of system lupus erythematosus (SLE). Higher levels of oxidative and nitrosative stress markers were found in SLE patients with greater disease activity suggesting a causal relationship

Researchers discover a link between arthritis and bacteria residing in the gut. On June 17, 2010 Harvard Medical School released a news alert containing information gained during a study focusing on the connection between bacteria found in the gut and arthritis.

Rheumatoid Arthritis And SLE Negatively Affect The Sex Lives Of Patients
Systemic Lupus Erythematosus (SLE) patients from Brazil and Rheumatoid Arthritis (RA) patients from France report that their rheumatic conditions negatively affect their emotional relationships and sex lives, according to research presented at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

Clinical Differences In Systemic Lupus Erythmatosus Patients May Be Affected By Genealogy
The effects of Systemic Lupus Erythematosus (SLE) may differ based on the individual patient's genealogical heritage, according to results of a new study presented at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy

Chinese systemic lupus erythematosus data reveal differences in epidemiology across continents Rome, Italy, Friday 18 June 2010: The Chinese Systemic Lupus Erythematosus (SLE) Treatment and Research Group (CSTAR) announced interim epidemiological information on SLE patients in China today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. Robust data on SLE patients has been scarce to date; but now CSTAR provides the first online registry of this magnitude in China. To date the registry has collated data from 2,104 SLE patients across 30 Chinese provinces.

Epratuzumab PhaseIIb study shows efficacy New data from EMBLEM� study shows pipeline drug epratuzumab provided significant efficacy for patients suffering from moderate to severe systemic lupus erythematosus

New Data Presented From EMBLEM� Study For Pipeline Drug Epratuzumab For Patients Suffering From Moderate To Severe Systemic Lupus Erythematosus UCB (Euronext: UCB) and Immunomedics, Inc. (Nasdaq: IMMU) announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE).

New Data Shows Epratuzumab Provided Significant Efficacy For Patients With Moderate To Severe Systemic Lupus Erythematosus UCB (EURONEXT: UCB) and Immunomedics Inc. (NASDAQ:IMMU) announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE).

NATURE Publishes New Dynavax Findings On Novel Role Of TLRs In Lupus Dynavax Technologies Corporation (NASDAQ: DVAX) today reported in NATURE new data that may explain the resistance of lupus patients to glucocorticoid treatment. In the June 16, 2010 issue of NATURE, Dynavax scientists show that activation of cells of the innate immune system by two key receptors, TLR7 and TLR9, can cause glucocorticoid resistance in lupus patients

Animal Study Sheds Light on Development of Lupus Nephritis Researchers hope to learn more about human lupus by figuring out how to make it develop in animals. A drug called polycytidylic acid (PCA) causes increased activity of immune system proteins called interferons (IFNs), which seem to play a role in the development of lupus. In mice that are already bred to be somewhat prone to lupus, the appearance of some features that look like the human disease, including lupus nephritis, are accelerated by giving PCA.

Risk Factors for Heart Disease in People with Lupus Although it is known that people with lupus are at greater risk for coronary heart disease (CHD), very little is known about which people with lupus really are at risk and which are not. Some studies have found that factors other than the �classic� CHD risk factors (i.e., high cholesterol or blood pressure, smoking, and a family history of CHD) may contribute to CHD risk. These include some features of lupus itself as well as some likelihood of additional risk factors from lupus treatments, especially steroids.

Which Women With Lupus Have Greater Risk for Human Papilloma Virus? This is a study of HPV infection in women with lupus, which examined the question of whether immune-suppressing treatments have any impact on the risk of HPV infection in women with lupus.

Human Genome Sciences Announces Submission of Biologics License Application to FDA for BENLYSTA Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval to market BENLYSTA� (belimumab) for the treatment of systemic lupus erythematosus (SLE).

Lupus Research Institute Hails Results of CellCept� Trial in People with Lupus Kidney Disease Persistence pays off as phase III study points to possible new treatment for this often deadly lupus complication

Rituximab Safe and Effective for Systemic Lupus Erythematosus In contrast to other trials, a French study shows the anti-CD20 monoclonal antibody rituximab to be well tolerated and clinically effective in patients with systemic lupus erythematosus (SLE).

New Study Demonstrates Improvements in Lupus Patients Receiving Stem Cell Therapies Lupus study shows promising results using umbilical cord mesenchymal stem cells

Immune Cell's Role in Lupus Nephritis Demonstrated, Paves Way for Safety Testing of Potential New Use for Asthma Drug National Institutes of Health scientists have discovered that the activation of immune cells called basophils causes kidney damage in a mouse model of lupus nephritis. These findings and the team�s associated research in humans may lead to new treatments for this serious disease, a severe form of systemic lupus erythematosus (SLE) that affects the kidneys and is difficult to treat.

Death Rates Still High in Lupus Nephritis Long-term mortality remains high among patients with lupus nephritis despite improvements in overall care for systemic lupus erythematosus (SLE), a Danish cohort study showed.

HUMAN GENOME SCIENCES ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION APPLICATION TO EMA FOR BENLYSTA� (BELIMUMAB) Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that GlaxoSmithKline (GSK) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval to market BENLYSTA� (belimumab) for the treatment of systemic lupus erythematosus (SLE).

Immune cell's role in lupus nephritis demonstrated National Institutes of Health scientists have discovered that the activation of immune cells called basophils causes kidney damage in a mouse model of lupus nephritis. These findings and the team's associated research in humans may lead to new treatments for this serious disease, a severe form of systemic lupus erythematosus (SLE) that affects the kidneys and is difficult to treat.

Clinical Trials in Lupus: What have We Learned so Far? - Understanding the gap between reality and expectation Despite the advances in understanding the aetiology and pathogenesis of SLE, a sobering fact is that no new drug has yet been licensed for its treatment. This is interesting when set against the backdrop of promising open-label experience with rituximab in particular. The apparent gap between expectation and reality raises questions about the true efficacy of these drugs, and whether trial design, outcomes measured or the choice of co-therapies have clouded the issue, running the risk that effective drugs may be inappropriately discarded. For the patient and physician, this gap translates into a longer wait for approved drugs to become available. So far, clinical trials have highlighted many observations and lessons that might help inform their future planning and execution.

La Jolla Pharmaceuticals gets $6 million infusion Struggling La Jolla Pharmaceuticals said Tuesday that it has found institutional investors to commit up to $6 million toward efforts to restart its business.

Center for Clinical Trials Education Adds Lupus RegistryThe LFA�s Center for Clinical Trial Education (CCTE) has expanded its services to provide registered participants notification of studies in their area. Sign up for the Lupus Research Registry and be notified of studies in your area that are actively recruiting participants. When an investigator alerts the LFA of a study, the LFA will send an email alert to registered individuals who live in areas that correspond to study sites. Registration is free and confidential.

Blood Components Help Differentiate Lupus and Antiphospholid Syndrome Some people have antiphospholipid syndrome without other forms of lupus, called primary antiphospholipid syndrome (PAPS). The researchers hoped to learn whether people with systemic lupus or PAPS had different amounts of TNF-α and sIL-2R in their blood.

Cognitive Behavioral Therapy Benefits People with Lupus Cognitive Behavioral Therapy (CBT) is a type of psychotherapy that explores the role of thinking in people�s well-being. One previous study investigated the effects of this treatment on stress in people with lupus. That study found that CBT, along with biofeedback, reduced pain and improved coping in people with lupus for up to nine months after the study was conducted.

Provision of preventive health care in systemic lupus erythematosus: data from a large observational cohort study IntroductionCancer and infections are leading causes of mortality in systemic lupus erythematosus (SLE) after diseases of the circulatory system, and therefore preventing these complications is important. In this study, we examined two categories of preventive services in SLE: cancer surveillance (cervical, breast, and colon) and immunizations (influenza and pneumococcal).

Rep. Riley and Sen. Hutchinson Push for Evaluation of Lupus Programs in Illinois State Rep. Al Riley (D-Olympia Fields) and state Sen. Toi Hutchinson (D - Olympia Fields) have passed a resolution urging Illinois health and human service agencies to assess state and federal programs that treat and study lupus to evaluate whether or not populations that are disproportionately affected by the disease have been educated about it and have access to proper treatment.

World of Lupus Research Expands as Florida Joins LRI National CoalitionAddition of State of Florida on World Lupus Day 2010 Pumps Extra Strength into Patient�s Voice for Lupus Research

Eduardo Xol From ABC's Extreme Makeover: Home Edition Bands Together With The Lupus Foundation Of America To Support Lupus Awareness Month
This May for Lupus Awareness Month, Eduardo Xol from ABC's Extreme Makeover: Home Edition has joined the Lupus Foundation of America to ask individuals to Band Together for Lupus� and commit to doing one thing to raise awareness of lupus

Important Control Mechanism Behind Autoimmune Diseases Discovered
Researchers at the Swedish medical university Karolinska Institutet have discovered a new control mechanism in our immune system. The discovery is of potential significance to the treatment of serious diseases such as MS (multiple sclerosis), rheumatoid arthritis, and SLE (Systemic lupus erythematosus).

Rescue NET for lupus patients Scientists at the Max Planck Institute for Infection Biology in Berlin together with medical scientists from the University of Erlangen succeeded in elucidating basic principles of the disease. This opens up new perspectives for methods that might enable early diagnosis and treatment of Lupus patients with a high risk at kidney failure.

Atherosclerosis in Children with SLE Investigators from Taiwan carried out a prospective study ofpatients with juvenile systemic lupus erythematosus (SLE) todetermine parameters associated with atherosclerosis.

Update on New Therapies in SLE Systemic Lupus Erythematosus: The Current State of Therapy.

Human Genome Sciences And GlaxoSmithKline Release Topline 76-Week Results For BENLYSTA
In July and November of 2009 Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) announced positive 52-week data for BENLYSTA� (belimumab) from two Phase 3 clinical trials, BLISS-52 and Bliss-76

Increased Levels of Circulating Microparticles in Primary Sj�gren's Syndrome, Systemic Lupus Erythematosus and Rheumatoid Arthritis and Relation with Disease Activity Cell stimulation leads to the shedding of phosphatidylserine (PS)-rich microparticles (MPs). Because autoimmune diseases (AIDs) are characterized by cell activation, we investigated level of circulating MPs as a possible biomarker in primary Sj�gren's syndrome (pSS), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Why lupus is more common in people of Asian and African descent A group of scientists think they've figured out why the autoimmune disease lupus afflicts people of Asian and African descent at higher rates than Caucasians. Their theory: A form of a gene that raises risk of lupus has a plus side -- rendering the carrier more resistant to malaria.

Lupus in Newborns Predicts Heart Block in Siblings Identification of cutaneous neonatal lupus in a child born to an autoantibody-positive mother is essential, because it predicts a high risk of congenital heart block in subsequent offspring, researchers warned.

ALR Announces 2010 TIL Grantees The ALR is awarding its first grants of the year to nine new investigators through its Target Identification in Lupus (TIL) program.

New Research Study To Follow Sisters Of Lupus Patients Scientists at The Feinstein Institute for Medical Research have embarked on a national search for sisters. The SisSLE (Sisters of Women with Systemic Lupus Erythematosus) research study is looking for sisters: one with a diagnosis of systemic lupus erythematosus (SLE), an autoimmune disease and one (or more) who does not have lupus.

Antimalarials and Mortality in Lupus: Should Hydroxychloroquine Be in the Water? In this long-term prospective observational study, as part of the Grupo Latino Americano de Estudio del Lupus Eritematoso (GLADEL) project, researchers from 9 Latin American countries investigated the relationship between antimalarial use and mortality in lupus.

Developments in the Clinical Understanding of Lupus Advances in genetics and new understanding of the molecular pathways that mediate innate and adaptive immune system activation, along with renewed focus on the role of the complement system as a mediator of inflammation, have stimulated elaboration of a scheme that might explain key mechanisms in the pathogenesis of systemic lupus erythematosus.

Earlier Steroid Treatment In Pediatric Lupus Patients Is Related to Higher Risk of Bone Disease Steroids are frequently used to treat moderate-to-severe lupus flares because they are highly effective and work quickly. However, steroids have many serious side effects, including potentially severe damage to joints or "osteonecrosis," which is an interruption of the blood supply to the bone. How much of a risk this may pose for children with lupus or younger adults with lupus has not been well-studied.

Urine May Help Track Kidney Disease and Predict Treatment Success in People With Lupus
Lupus nephritis (LN) - inflammation of the kidney - can damage the kidney�s ability to remove waste from the body. Currently, the best way to diagnose kidney inflammation is with a biopsy, an invasive procedure that can sometimes have serious side effects. Researchers have been working to develop specific tests that could be done on urine that could evaluate kidney disease without a biopsy, something that could be a major advance for people with lupus

Low Level of Vitamin D Does Not Necessarily Result in Bone Disease in People With Lupus
People with lupus are advised to avoid the sun because the ultraviolet rays can trigger rashes. Some patients experience more widespread flares after sun exposure. However, sun avoidance leads to low levels of vitamin D in the body. Low levels of vitamin D are associated with thinning of the bones, or "osteoporosis." Steroids are often used to treat lupus since they work fast and are highly effective, but they can also increase osteoporosis. For these reasons, among others, people with lupus are at increased risk for osteoporosis.

HHMI's Gilliam Fellowships Aim To Increase Diversity In The Sciences
The Howard Hughes Medical Institute (HHMI) has selected five exceptional individuals to receive the 2010 Gilliam Fellowships for Advanced Study. These students will join a dynamic group of 30 Gilliam fellows, who share a passion for science and a commitment to increasing diversity in the sciences.

Advocates Seek Increased Federal Funding To Bridge The Gaps In Lupus Research, Awareness, And Education
On March 16, 2010, an anticipated 1,000 advocates will band together for lupus in person and virtually by phone, email, and through social media networks, to share their personal stories with Members of Congress during the Lupus Foundation of America's, (LFA) Twelfth Annual Advocacy Day.

10 Mar 2010

Psychotherapy May Help Autoimmune Disease
This study shows that cognitive behavioural therapy (CBT) is effective in dealing with patients suffering from lupus and high levels of daily stress as it significantly reduces the incidence of psychological disorders associated with lupus and improves and maintains patients' QOL, despite there being no significant reduction in the disease activity index.

04 Mar 2010

Antibodies Linked To Cardiovascular Disease Increase In Patients With Active Lupus A study by researchers in Australia and the United Kingdom suggests that autoantibodies to fat binding proteins significantly increase in systemic lupus erythematosus (SLE) patients with active disease.

26 Feb 2010

Cyclosporine an Effective Corticosteroid-Sparing Agent in Severe SLETo avoid steroids in patients with severe systemic lupus erythematosus (SLE), cyclosporine can be used when azathioprine isn't tolerated, British researchers say. 24 Feb 2010
Hydroxychloroquine Delays Onset of Integument Damage in Lupus The antimalarial hydroxychloroquine appears to significantly delay the onset of integument damage in patients with systemic lupus erythematosus, a new study shows.24 Feb 2010

An Early Study of a New Treatment (Tocilizumab) for Lupus Interleukin-6 (IL-6) is a protein that helps to control inflammation in the body. People with lupus sometimes have increased IL-6 in the blood, and some studies suggest that IL-6 might increase with lupus flares. If the activity of IL-6 could be blocked, it might help to decrease inflammation.

19 Feb 2010

Can Blood Tests Help Us Learn about CNS Lupus (Lupus and the Brain)? In some people with lupus, mild or, more rarely, severe inflammation of the brain, also called Central Nervous System lupus (CNS lupus), can occur. Sometimes it is hard to know the difference between CNS lupus and problems that might be due to fatigue, depression, or migraine headaches. Therefore, it would be helpful to have blood tests that could tell the difference, so appropriate treatments could be given.

19 Feb 2010

Study Finds Risk Factors for Heart Disease in People With Lupus Some people with lupus seem to be at increased risk for heart disease. It would be very helpful to know about specific factors that could help to predict this risk. The researchers hoped to learn what characteristics of people living with lupus might help to predict heart disease.

19 Feb 2010

Twin Study Seeks to Unravel Genetic Clues to Lupus Development DNA contains the blueprints for all the proteins in the body. DNA is wound up in tight coils and when a cell wants to make a protein, these coils unravel to expose the instructions for making that protein. The degree to which DNA stays tightly coiled or loosens up is influenced by whether or not chemicals called "methyl groups" are attached to specific parts of the DNA. The researchers hoped to find out if DNA methylation is different between twins when one twin has lupus and the other does not.

19 Feb 2010
Predictors of Major Infections in Systemic Lupus Erythematosus Infections commonly complicate the course of systemic lupus erythematosus (SLE). Our aim is to investigate the clinical predictors of major infections in patients with SLE.
Molecular Therapies for Systemic Lupus Erythematosus: Clinical Trials and Future Prospects The prognosis of patients with systemic lupus erythematosus has greatly improved since treatment regimens combining corticosteroids and immunosuppressive medications have been widely adopted in therapeutic strategies given to these patients. Immune suppression is evidently efficient but also leads to higher susceptibility to infectious and malignant diseases.

Testing For Urinary Proteins Might Help Diagnose Kidney Damage From Lupus Simple urine tests for four proteins might be able to detect early kidney disease in people with lupus, researchers at UT Southwestern Medical Center have found in an animal study. Although it might take years before such tests could be used clinically, the findings suggest they could pinpoint kidney disease better than tests currently in use, the researchers said.

16 Feb 2010

Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. DNA contains the blueprints for all the proteins in the body. DNA is wound up in tight coils and when a cell wants to make a protein, these coils unravel to expose the instructions for making that protein. The degree to which DNA stays tightly coiled or loosens up is influenced by whether or not chemicals called "methyl groups" are attached to specific parts of the DNA.16 Feb 2010

LFA President Presents At The 12th Annual BIO CEO And Investor Conference
During the 12th Annual BIO CEO and Investor Conference held on Tuesday, February 9, 2010 in New York City, Sandra C. Raymond, President and CEO of the Lupus Foundation of America (LFA), participated in a panel discussion on the future of potential new treatments for lupus.

12 Feb 2010

Copyright © 2006-2014 Cure4Lupus.org. Powered by Zen Cart  All rights reserved.
17668 I St., Omaha, NE 68135
Webmaster@Cure4Lupus.org 402-718-5002

Text on this page may be copied and reposted if there is a link to this site posted with it.

This is not a medical website and information on this site should never be substituted for medical advice. Always consult a physician before making any medical decisions!

Cure4Lupus.org is a philanthropic organization. It is not a 501(c)3 non-profit organization. It donates most profits to 501(c)3 organizations, however it is a for profit business independent of the Lupus Foundation of America or any other organization.